Akari Therapeutics Plc EV/EBIT
Was ist das EV/EBIT von Akari Therapeutics Plc?
EV/EBIT von Akari Therapeutics Plc ist N/A
Was ist die Definition von EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Akari Therapeutics Plc
Was macht Akari Therapeutics Plc?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Unternehmen mit ev/ebit ähnlich Akari Therapeutics Plc
- Canadian General Investments hat EV/EBIT von N/A
- Omnia Metals Ltd hat EV/EBIT von N/A
- Netgear Inc hat EV/EBIT von N/A
- Vroom hat EV/EBIT von N/A
- OncoSec Medical Inc hat EV/EBIT von N/A
- Hemogenyx Pharmaceuticals Plc hat EV/EBIT von N/A
- Akari Therapeutics Plc hat EV/EBIT von N/A
- Youngevity International Inc hat EV/EBIT von N/A
- Sigma Labs Inc hat EV/EBIT von N/A
- GOLO Mobile hat EV/EBIT von N/A
- NeuroOne Medical Technologies hat EV/EBIT von N/A
- Vision Marine Technologies hat EV/EBIT von N/A
- Medicenna Therapeutics hat EV/EBIT von N/A